January 7, 2019
DiscGenics’ cell therapy IDCT passes the Initial Safety Review of its first-in-human clinical trial for degenerative disc disease
DiscGenics’s IDCT cell therapy has passed the initial planned safety review of its Phase I/II trial evaluating the allogeneic, injectable disc cell therapy in patients with mild to moderate degenerative disc disease (DDD).